The earnings call presented a mix of positive progress in clinical trials and commercial performance, especially with a steady increase in revenue from XPOVIO and global expansion efforts. However, significant financial challenges due to a net loss, decline in total revenue, and approaching debt maturity are concerning. The company is actively working on strategic alternatives to enhance liquidity.

Company Guidance

During the second quarter of 2025, Karyopharm Therapeutics reported XPOVIO net product revenue of $29.7 million, reflecting a 6% increase from the same period in 2024. The company anticipates full-year 2025 net product revenue to be in the range of $110 million to $120 million. The gross-to-net provision for XPOVIO was 26.8% in Q2 2025, a decrease from 45% in Q1 2025 and 29.3% in Q2 2024. R&D expenses decreased by 15% compared to the second quarter of 2024, aligning with the company's cost optimization initiatives, while SG&A expenses saw an 8% reduction. Despite a net loss of $37.3 million for the quarter, Karyopharm is optimistic about its Phase III clinical trials, including the SENTRY trial for myelofibrosis and the EMN29 SPd trial for multiple myeloma, with potential peak annual revenue of up to $1 billion in the U.S. from the myelofibrosis opportunity alone.

Solid Commercial Performance

The company delivered solid commercial results in Q2 2025, with XPOVIO net product revenue of $29.7 million, up 6% from the second quarter of 2024. Demand for XPOVIO remained consistent, driven by the community setting.

Progress in Clinical Trials

Enrollment in the Phase III SENTRY trial for myelofibrosis is expected to close soon. Preliminary safety data suggest that the combination of selinexor and ruxolitinib may have a favorable safety profile.

Global Expansion

Selinexor and NEXPOVIO are now approved in various indications in 50 countries, leading to a 28% increase in royalty revenue to $1.6 million in Q2 2025 compared to Q2 2024.

Cost Reduction Initiatives

R&D expenses decreased by 15%, and SG&A expenses decreased by 8% in Q2 2025 compared to Q2 2024, reflecting the realization of cost optimization efforts.

Karyopharm Therapeutics (KPTI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KPTI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-3.40 / -	-3.9	―	―	―
Aug 11, 2025	2025 (Q2)	-4.08 / -4.32	-3	-44.00% (-1.32)
May 12, 2025	2025 (Q1)	-4.42 / -2.77	-4.8	42.29% (+2.03)
Feb 19, 2025	2024 (Q4)	-3.92 / -3.60	-5.4	33.33% (+1.80)
Nov 05, 2024	2024 (Q3)	-3.94 / -3.90	-4.5	13.33% (+0.60)
Aug 06, 2024	2024 (Q2)	-4.47 / -3.00	-4.35	31.03% (+1.35)
May 08, 2024	2024 (Q1)	-5.01 / -4.80	-4.5	-6.67% (-0.30)
Feb 29, 2024	2023 (Q4)	-4.65 / -5.40	-6.45	16.28% (+1.05)
Nov 02, 2023	2023 (Q3)	-4.20 / -4.50	-6.75	33.33% (+2.25)
Aug 02, 2023	2023 (Q2)	-5.13 / -4.35	-9.3	53.23% (+4.95)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KPTI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$3.94	$3.77	-4.31%
May 12, 2025	$6.15	$4.92	-20.00%
Feb 19, 2025	$9.45	$9.00	-4.76%
Nov 05, 2024	$14.00	$12.68	-9.43%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Karyopharm Therapeutics (KPTI) report earnings?

Karyopharm Therapeutics (KPTI) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is Karyopharm Therapeutics (KPTI) earnings time?

Karyopharm Therapeutics (KPTI) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KPTI EPS forecast?

KPTI EPS forecast for the fiscal quarter 2025 (Q3) is -3.4.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing